CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study.
about
CD30 is a potential therapeutic target in malignant mesotheliomaNovel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive reviewNucleic Acid Aptamers as Potential Therapeutic and Diagnostic Agents for Lymphoma.Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries.Prognostic significance of CD30 expression in nasal natural killer/T-cell lymphoma.CD30 expression in extranodal natural killer/T-cell lymphoma, nasal type among 622 cases of mature T-cell and natural killer-cell lymphoma at a single institution in South China.Prognostic significance of pleural or pericardial effusion and the implication of optimal treatment in primary mediastinal large B-cell lymphoma: a multicenter retrospective study in Japan.Brentuximab vedotin for relapsed or refractory Hodgkin's lymphoma.Diffuse large B-cell lymphoma classification system that associates normal B-cell subset phenotypes with prognosisThe expression of CD30 based on immunohistochemistry predicts inferior outcome in patients with diffuse large B-cell lymphomaThe oncogenic transcription factor IRF4 is regulated by a novel CD30/NF-κB positive feedback loop in peripheral T-cell lymphoma.Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma in the Elderly: A Matched Case-Control Analysis.Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries.Epstein-Barr virus positive diffuse large B-cell lymphoma predict poor outcome, regardless of the age.Does cell-of-origin or MYC, BCL2 or BCL6 translocation status provide prognostic information beyond the International Prognostic Index score in patients with diffuse large B-cell lymphoma treated with rituximab and chemotherapy? A systematic review.Prevalence and clinicopathologic features of CD30-positive de novo diffuse large B-cell lymphoma in Chinese patients: a retrospective study of 232 casesp63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function.Advances in the treatment of hematologic malignancies using immunoconjugatesPrimary mediastinal large B-cell lymphoma: transcriptional regulation by miR-92a through FOXP1 targeting.Role of CD30 targeting in malignant lymphoma.Prognostic factors, prognostic indices and staging in mycosis fungoides and Sézary syndrome: where are we now?New therapies in non-Hodgkin lymphoma.CD 30-positive transformed follicular lymphoma: two case reports and literature review.CD30 Expression in Pediatric Neoplasms, Study of 585 Cases.Diffuse Large B-cell lymphoma: Prognostic markers and their impact on therapy.New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma.Expression patterns of the activator protein-1 (AP-1) family members in lymphoid neoplasms.CD30 and CD30-Targeted Therapies in Hodgkin Lymphoma and Other B cell Lymphomas.Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry.Evaluation of NF-κB subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions.CD30 expression and its correlation with MYC rearrangement in de novo diffuse large B-cell lymphoma.Primary CD30-positive Diffuse Large B-cell Lymphoma in the Superior Vena Cava.Occurrence and prognostic relevance of CD30 expression in post-transplant lymphoproliferative disorders.EBV-negative monomorphic B-cell post-transplant lymphoproliferative disorders are pathologically distinct from EBV-positive cases and frequently contain TP53 mutations.CD30 expression in de novo diffuse large B-cell lymphoma: a population-based study from British Columbia.Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program.Outcomes among US patients with diffuse large B cell lymphoma are independent of tumor Epstein Barr virus positivity or immunosuppression.CD30 Expression in Monomorphic Posttransplant Lymphoproliferative Disorder, Diffuse Large B-Cell Lymphoma Correlates With Greater Regulatory T-Cell Infiltration.Is CD30 a predictive biomarker for brentuximab vedotin?Advances in systemic therapy for malignant mesothelioma: future perspectives.
P2860
Q23921491-B132B02F-10C8-4818-8127-3C78145AC131Q27304386-EC54D923-3156-4FC2-910D-E76EF3529A55Q30434521-8772557B-12B2-4C03-A8A5-7F72E30B233FQ33583294-CE92A28C-9596-4C4B-B42A-486C89E3309FQ33598637-378EA96C-2455-4778-A217-F22A1036A284Q33655362-52C15B7E-EC85-473B-B468-3E98DAE06C07Q34649109-EFC168F2-F8BA-43A3-9A6D-2EA312FFCBC6Q35223221-9FE89AB9-260C-4F34-ADCF-A113D7BE990CQ35419876-4A438F45-C676-4BF4-917B-1E5EB90D5061Q35606714-D2B28FF5-4828-4493-9848-4D210F94537AQ35607281-10E2085C-C5D9-489B-B68C-E9F442AD3864Q35723777-CDF63A72-98C5-4022-806E-9F34F6783916Q35742367-71017DA4-0346-451D-9ABD-A23898035304Q35880791-752EF598-C3F5-46D5-9F59-10EA02877A97Q36302961-737A5847-0B5B-4C13-A5CE-7A0337E45926Q36511738-16D5C43E-1FB9-405F-A4ED-ADA59261B2A5Q36681461-846D3861-ABB2-4803-A0E5-554393FAE0D6Q37697843-60BBF33D-3730-4764-97B1-6872230693CAQ37725413-27919830-0386-4496-A161-7E8E5949BA8BQ38191191-80BE415D-5CCD-401F-BB57-D3367C9E1FD5Q38196931-AF93FE53-01BF-4C02-A6A7-869C966ABA5BQ38315779-950ED6FF-5937-4727-85DC-A57C521C829FQ38466350-E46332AB-06B4-4E2E-9197-1A6CCEE18777Q38682195-2631663A-0F00-490F-9CF9-965BDF385B24Q38710832-572F18B9-130B-4A1C-9882-559E29BA7C2CQ38896683-53D09BB4-CD8A-4C44-80A2-32652EEFA3BFQ38947647-168D1B96-CB01-4BE1-97E2-B674BE99E169Q38950501-2A525AEF-1B72-447C-B8C8-69AEA87B17E0Q40422243-C0B1327D-11E9-4508-8F52-FFE288F4ABADQ40796551-276B2F2C-FD80-4E3F-A181-CB5A1F9C370FQ41411254-EB64573C-0336-4F6F-BF5D-DFC58F7583C1Q41564189-E81AA5B4-202E-4485-BE52-92EA80A09508Q41728703-84F85E80-F34F-402E-8452-46A0F27E8476Q42051829-27A3CA20-5635-41A6-9DE8-F4FA2863E98EQ42199195-B4E4FD31-CE6B-47D9-8352-F27BE6DA398BQ42230312-F889A28C-4844-451E-A73C-741FD36C75AAQ45324330-4B47DD41-416B-48A7-8E82-0D1FCDE3E5F4Q47416235-A441AEA8-43A6-4F1D-823E-393D06D5F8A6Q47584171-4EB5366A-3E41-4EA4-A052-56028F6C0122Q47912434-2E681410-9A89-4D6A-9CF7-13AC98770A23
P2860
CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
CD30 expression defines a nove ...... CHOP Consortium Program Study.
@en
type
label
CD30 expression defines a nove ...... CHOP Consortium Program Study.
@en
prefLabel
CD30 expression defines a nove ...... CHOP Consortium Program Study.
@en
P2093
P2860
P50
P1433
P1476
CD30 expression defines a nove ...... CHOP Consortium Program Study.
@en
P2093
Aarthi Balasubramanyam
Alexander Tzankov
Andrés J M Ferreri
April Chiu
Attilio Orazi
Carlo Visco
Eric D Hsi
J Han van Krieken
Jooryung Huh
Ken H Young
P2860
P304
P356
10.1182/BLOOD-2012-10-461848
P407
P50
P577
2013-01-23T00:00:00Z